Galmed Pharmaceuticals Ltd.

Two days after the quarterly earnings call on which Madrigal Pharmaceuticals, Inc. unveiled the initial sales results for Rezdiffra (resmetirom), the first approved drug for non-alcoholic steatohepa

Akero Therapeutics, Inc. ’s Phase II FGF21 analog efruxifermin (EFX/AKR-001) demonstrated the ability to reduce fibrosis score by one stage or more in non-alcoholic steatohepatitis patients with cirrh

No M&A Mania But Major Deals Still Unsurprisingly, M&A activity in 2020 was less frantic than pre-pandemic days and the year was not dominated by mega-mergers such as in 2019 when Bristol Myers Squib

This year began with the expectation of the first drug approval in non-alcoholic steatohepatitis, with a number of other Phase III programs right on the lead product’s heels. But instead, the year is